AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) –
Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in th
AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S
Biosimilar competition to AbbVie’s cash-cow product Humira ramped up in the first quarter, but more worrying for the company was disappointing growth among the products it
AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new ind
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl